In order to prevent EBV-LPD after TCD allo-SCT we performed a prospective phase II study evaluating the efficacy of anti B-cell immunotherapy as PE-therapy guided by quantitated levels of EBV viral load. Retrospectively, a viral load of 1,000 EBV genome equivalents per ml (geq/ml) was associated with a positive predictive value (PV+) of 39% and a PV-of 100% following TCD-allo-SCT. That threshold was chosen for PE by a single infusion of Rituximab (375 mg/m2). Forty-nine recipients of a TCD-allo-SCT were included in this study, 35 received stem cells from a family donor (sib) and 14 from a matched unrelated donor (MUD). Patients were monitored weekly for EBV-reactivation (Ͼ 50 geq/ml) by quantitative real-time Taqman PCR. Forty-three donor/recipient (D/R) combinations were EBV-seropositive, 3 were D-/R+ and 3 D+/R-. EBV-reactivation occurred in 49% (24/49) of patients. Twelve patients showed EBV-reactivation Ͼ = 1,000 geq/ml and received PE (8 sib, 4 MUD) at a median EBV-DNA level of 3,600 (range 300-86,300). Median time to EBV-DNA Ͼ = 1,000 geq/ml was 120 days (range 39-507), and median time to initiation of PE was 125 days (range 43-514) following SCT. Eleven patients showed complete clearance of EBV-DNA from plasma within a median of 6 days (range 1-46) after PE and did not develop EBV-LPD. Only one recipient of a MUD-SCT developed EBV-LPD despite PE, but obtained complete remission (CR) after 2 infusions of Rituximab and donor lymphocyte infusion. Two recipients of a MUD-SCT presented with EBV-LPD before initiation of PE. Viral reactivation was directly followed by LPD in both cases. These patients showed a CR on repeated Rituximab infusion guided by EBV-DNA levels and are alive to date. B-cell numbers prior to initiation of PE were 0.05 (10E9/l) (range 0.009-0.22) (reference value 0.04-0.28) and became undetectable 24 hours after PE. B-cell recovery after PE took Ͼ 6 months in most patients. In conclusion, PE with a single infusion of Rituximab given at EBV-DNA Ͼ = 1,000 geq/ml in recipients of a TCD-allo-SCT is an effective strategy to decrease the incidence of EBV-LPD.
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The therapeutic potential of Interleukin-18 (IL-18) blocking antibodies in Graft Versus Host Disease (GVHD)
A. Nagler, D. Novick, M. Ohana, G. Zecchina, C.A. Dinarello, V. Barak (Jerusalem, Rehovot, IL; Denver, USA) Dysregulation of the cytokine network has been shown to play an important role in the induction and maintenance of GVHD in experimental models and humans. IL-18 is an obligatory cytokine for interferon gamma (IFN-g) production, and we have previously demonstrated that IFN-g and soluble INF-g receptor (sIFN-gR) are elevated in pts. with GVHD. IL-18 binding protein (IL-18BP) is an inhibitor of IL-18 mediated IFN-g production. We evaluated IL-18 levels in 23 pts. with acute GVHD at various time points and stages of their disease. IL-18 was assessed by sensitive radioimmunoassay and IL-18BP by specific McAB and double-sandwich Elisa. In normal controls IL-18 and IL-18BP levels were 40+5pg/ml and 2.5+2ng/ml, respectively. In acute GVHD pts. IL-18 levels were found to be markedly elevated (315+29pg/ml), while they were lower pre-conditioning, at day of engraftment and post-uneventful transplantation (96+9, 85+5 and 118+21pg.ml, respectively (pϽ0.05)). Similarly, IL-18BP increased in pts. with acute GVHD (15.1+3.1pg/ml) (pϽ0.001), in parallel to sIFN-gR. We then tried to alleviate GVHD with anti IL-18 blocking antibodies (aIL-18Ab) in a murine model. GVHD was generated by transplanting 2x107 splenocytes from C57BL/6 (H2b) donor mice into (C57BL/6x BALB/c) F1 (H-2b/d) mice which had received 700cGy total body irradiation prior to transplantation. The study group received 2 doses of aIL-18Ab (I.V), one on day of transplantation and the other 7 days later, while the control group received I.V. saline. The mice were monitored daily for clinical GVHD parameters (weight loss, diarrhea, cachectic appearance, ruffled skin) and survival. Anti IL-18Ab significantly reduced the mixed lymphocyte reaction (MLR) response in vitro. Clinical parameters of GVHD including weight loss improved in mice treated with anti IL-18Ab (weight on day +8 was 21.7+ 0.8 gr. compared to 17.7 + 0.5 gr. for untreated mice. Similarly, survival was significantly higher in mice treated with anti IL-18Ab (pϽ0.02). In conclusion, blocking IL-18, which has been found to be elevated in GVHD and which may be the mediating factor in the cause of the increase in IFN-g and sIFN-gR levels, may have therapeutic potential in GVHD. Backgroung: Among the complications of high-dose chemotherapy, hepatic veno-occlusive disease (HVOD) is one of the major factors limiting dose-intensity chemotherapy. The cells lining the vascular endothelium and hepatocytes carry blood group A and/or B antigens on their surface according to the blood group of the patient. We therefore designed a study evaluating the potential impact of ABO-incompatible plasma transfused with platelet concentrates (PC) in young children at high risk of HVOD. Methods: Betwween 1988 and 1998, 186 young children (median age: 4 years [0.75-17] consecutively conditioned with high-dose busulfan-containing regimens followed by haematopoietic stem cell transplantation for neuroblastoma (n=112) or a brain tumor (n=74) were investigated. The main endpoint was the time to onset of HVOD from the start of conditioning chemotherapy. The period of interest thus began on the first day of chemotherapy and continued up to onset of HVOD or discharge from the hospital in the absence of HVOD. A univariate and multivariate analysis of the occurence of HVOD were performed using Cox's regression model with potential time-dependent covariates. Findings: 73/186 (39%) children developped HVOD during their hospitalisation. The multivariate analysis showed that two independent factors significantly increased the occurence and precipitated the onset of HVOD: transfusion of ABO-incompatible plasma with PC (p=0.003) and the combination of melphalan with busulfan in the conditioning regimen (p=0.006). Conversely, the number of platelet transfusion/week, recipient age, sex as well as use of cyclophosphamide in conditioning regimen, had no effect on the occurence of HVOD. Interpretation: The hypothesis proposed is that the interlocking of anti-A and/or B antibodies on the A and/or B antigens expressed on the surface of endothelium cells and/or hepatocytes of children whose blood group is A, B or AB promotes HVOD. These results dictated a change in our transfusion strategy. Transfusion of PC presenting plasma ABO-incompatibility should be avoided in young children who are treated with busulfan-containing regimen. Background: In the early 90's 4 trials compared conditioning with either Bu-Cy or Cy-TBI. In all 4 studies the association of CSA and MTX was used as GvHD prophylaxis. Trials were reported with follow-up ranging from 24 to 42 months. In 3 studies the disease free survival (DFS) rates were similar after conditioning with either Bu-Cy or Cy-TBI. While both conditioning have now gained wide acceptance long-term follow-up is lacking. Aims: 1) to compare long-term survival, return to work and general health status in patients according to conditioning; 2) to estimate incidence rates and look for risk factors of late complications. Results: Data on 316 patients with CML and 172 patients with AML are available, with a mean follow-up of over 7 years for surviving patients. In patients with AML 38% (Bu) and 28% (TBI) died leading to a 10-year survival rate of 59.2% vs 69.5%, p = 0.4. In patients with CML 29% (Bu) and 28% (TBI) died leading to a 10-year survival rate of 69.4% vs 67.3%, p = 0.9. The WHO score at last follow-up estimated general health status. Most patients had either normal health status (WHO score = 0) or minimal impairment. Data on return to work was available in 160 patients (not available for the FHCRC trial). 80% of the patient went back to work/school without difference using either conditioning. Cataract incidence rate reached 12.3% vs 12.4% in AML (p = 0.82) and16% vs 47% (p = 0.001) in CML patients receiving Bu-Cy or Cy-TBI, respectively. Risk factors associated with an increased rate of cataract included TBI (Hazard ratio (HR) 2.28, p=.0008) and CML (RR=3.32, p=.005). Late pulmonary disease occurred in 6% vs 6% in patients with AML patients and in 15% vs 15% of CML patients receiving Bu-Cy or Cy-TBI, respectively. Multivariable analysis found CML (HR=4.9, p=.002) and chronic GvHD (HR=3.1, p=.0007) as significant factor associated with this complication. Avascular osteonecrosis occurred in 6% vs 7% of patients with AML and in 3% vs 10% of CML patients receiving Bu-Cy or Cy-TBI, respectively. Multivariable analysis found younger age (HR=0.94, p=.002) and chronic GvHD (HR=6.35, p=.0009) as significant factors. Hypothyroidism was rarely reported (6 cases, overall) as well as hyperthyroidism (1 case).Persistent impairment with hair re-growth was assessable in 194 patients (data not available FHCRC) in 72% and 55% of the patients receiving Bu-Cy or Cy-TBI, respectively and was associated with chroinc GvHD (OR=3, p=.01) and Bu (OR=2, p=.02). CMV infection remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). Reconstitution of CMV-specific cytotoxic T-lymphocytes (CTLs), predominantly directed against the tegument protein pp65, was found to provide protective immunity after allogeneic SCT. However, only few CTL epitopes have been characterized up to now. In an attempt to define pp65 CTL-peptides, a computer-based epitope prediction using the SYFPEITHI database was performed for the MHC class I restrictions A*0101, A*0201, A*0301, A*1101, B*0702, B*0802 and B*3501. All predicted peptide-epitopes were loaded on antigen-presenting cells and CTL responses assessed by an INFg-ELISPOT assay. By this approach, we were able to identify 4 pp65-peptides presented by the HLA-alleles A*0101, A*0201, A*1101 and B*0702. The frequency of peptide-specific CTLs in healthy CMV-seropositive individuals as assessed by flow cytometry after peptide stimulation varied considerably, ranging from 0.2 to 1.4% of all CD8+ T-cells. A higher frequency of HLA-B*0702 restricted compared to HLA-A*0201 restricted CMV-peptide specicifc T-cells was found in 3 CMV-seropositive healthy individuals. In 7 out of 9 recipients of allogeneic stem cells from a CMV-seropositive donor, CMV peptide-specific CTLs were documented already on days 30 to 60 posttransplantation in a frequency ranging from 0.1 to 14.8% of all CD8+ T-lymphocytes as assessed by intracellular INFg-staining by flow cytometry. In only 1/5 CMV-seropositive patients receiving a transplant from a CMV-seronegative donor, peptide-specific T-cells were found in a low frequency. CMV-antigen specific CD4+ T-lymphocytes were found in 8/9 patients analysed in a frequency ranging from 0.1 to 5.7%. All patients showing peptide-specific T-cell responses also demonstrated lymphoproliferative responses to CMV, PHA and IL-2 and showed rapid clearance of CMV infection upon antiviral therapy. In conclusion, the epitope-prediction model provided by the SYFPEITHI software and an INFg-ELISPOT assay allowed to define previously unknown CTL-epitopes processed during natural CMV infection. Monitoring of peptide-and protein-specific T-cell responses allowed to assess the CMV-specific immune reconstitution after allogeneic SCT. Further CTL-and also HTL-epitopes need to be identified to allow monitoring of peptide-specific T-cell responses in the majority of patients after allogeneic SCT.
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In situ dissection of graft-versus-host disease and graft-versus-leukaemia effect by minor antigen specific cytotoxic T-cells X.N. Wang, A.M. Dickinson, L. Sviland, J. Dunn, G.H. Jackson, T. Mutis, E. Goulmy (Newcastle upon Tyne, UK; Bergen, N; Leiden, NL)
Minor histocompatibility antigens (mHags) play important roles in stem cell transplantation (SCT). Depending on their tissue distribution, mHags serve as target antigens for graft-versus-host disease (GvHD) or graft-versus-leukaemia (GvL) activities. In this study an ex vivo human skin explant model was used to investigate the graft-versus-host reactions (GvHR) induced by CTLs specific for the haematopoietic restricted mHags HA1/HA2 and by CTLs specific for the ubiquiously expressed H-Y mHags. Skin sections were co-cultured with specific test CTLs and control CTLs and the GvHR was graded as I to IV according to the severity of histopathological tissue damage. The results showed that HY specific CTLs induced severe skin GvHR (grade III-IV) in 10 out of 10 experiments while no more than grade I GvHR was observed with control CTLs. The severe skin GvHR induced by HY specific CTLs were significantly associated with high levels of IFN-gamma production (1102pg/ml and 49.8pg/ml for test CTLs and control CTLs respectively). Immunohistochemistry staining demonstrated high numbers of CD8+ T cells present at the tissue damage site of the skin sections with GvHR grade III-IV. Most importantly, in all experiments wherein the haematopoietic system restricted HA-1 (N-7/7) or HA-2 (N=8/8) specific CTLs were used: no significant GvHR was observed, neither could IFNgamma levels be measured. In conclusion, this ex-vivo skin explant model clearly demonstrates that the broadly expressed mHags but not the haematopoietic system restricted mHags are the prime GvHD targets. These results underline the importance of the adoptive immunotherapy of leukaemia with HA-1 and HA-2 specific CTLs.
